Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights - Episode 7

Differentiating Treatment Options: Epcoritamab + R2 vs Tafasitamab-Lenalidomide-Rituximab in R/R FL

January 25, 2025

Panelists discuss how they anticipate differentiating candidates for epcoritamab + lenalidomide and rituximab (R2) vs those better suited for tafasitamab-lenalidomide-rituximab, considering the factors that most influence their decisions, and share their impressions of the EPCORE NHL-2 trial, including potential treatment sequencing implications between the 2 regimens.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease

EP. 2: Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease

EP. 3: ASH 2024 Updates: inMIND study With Tafasitamab Combined With Lenalidomide and Rituximab in R/R FL

EP. 4: Expert Insights: How Tafasitamab + R2 May Impact Clinical Practice in R/R FL

EP. 5: Exploring Tafasitamab in 2L Treatment: Challenges, Impact on Decision-Making, and Key Insights From inMIND Study

EP. 6: ASH 2024 Updates: EPCORE NHL-2 Trial With Fixed-Duration Epcoritamab + R2

Now Viewing

EP. 7: Differentiating Treatment Options: Epcoritamab + R2 vs Tafasitamab-Lenalidomide-Rituximab in R/R FL

EP. 8: Choosing Bispecifics in 3L Treatment Setting R/R FL

EP. 9: ASH 2024 CAR T and Bispecifics Updates: Key Insights and Practical Considerations in 3L R/R FL Treatment

EP. 10: Navigating the Evolving Treatment Landscape in R/R FL: When to Consider BTK and EZH2 Inhibitors

EP. 11: Expert Perspectives: Sequencing Tafasitamab + R2 With Currently Available Options in 3L Setting

EP. 12: Reflecting on 2024: Key Achievements and Looking Ahead to 2025 in R/R FL Treatment

Video content above is prompted by the following:

How do you anticipate differentiating candidates for epcoritamab[JS1] + R2 and those who might be better suited for a tafasitamab-lenalidomide-rituximab? What factors most influence your decision?
Feel free to share your thoughts on any differences and/or similarities in your impressions of the EPCORE NHL-2 trial, and potential treatment sequencing implications between tafasitamab-lenalidomide-rituximab vs epcoritamab + R2.